Induced pemphigus erythematosus after treatment for plaque psoriasis with secukinumab: a case report
Secukinumab is a fully human monoclonal antibody that specifically targets and neutralizes interleukin (IL)-17A, a cytokine typically involved in the mucocutaneous defense against pathogens. Despite its favorable safety profile, serious adverse events …